Clinical Trials Search
Advanced
Filter by theraputic area:
Filter by phase:
Filter by status:

Active trials only:
Trials portfolio
ACTOv
Adaptive ChemoTherapy for Ovarian cancer: A multicentre phase II randomised controlled trial to evaluate the efficacy of Adaptive Therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high grade serous or high grade endometrioid ovarian cancer
ACTOv is a multicentre, phase II randomised controlled trial to evaluate Adaptive Therapy (AT) with carboplatin in women with relapsed platinum-sensitive high grade serous or high grade endometrioid c [...]
Area: Gynaecological cancer
Phase: Phase II
Status: Active (recruiting)
ICON9
An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
ICON9 is an international phase III randomised study to evaluate the efficacy of maintenance olaparib and cediranib combination therapy or olaparib alone in patients with relapsed platinum-sensitive o [...]
Area: Gynaecological cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
INTERLACE
A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation vs standard chemoradioation alone in patients with locally advanced cervical cancer
INTERLACE is a phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer.
Area: Gynaecological cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
METRO-BIBF
Phase II, randomised, placebo controlled, multicentre, feasibility study of low dose (metronomic) cyclophosphamide with or without nintedanib (BIBF1120) in advanced ovarian cancer (METRO–BIBF)
METRO-BIBF is a phase II, randomised, placebo-controlled, multi-centre, feasibility study of low dose (metronomic) cyclophosphamide with and without nintedanib (BIBF 1120) in advanced ovarian cancer.
Area: Gynaecological cancer
Phase: Phase II
Status: Closed
NSMP-ORANGE
RAINBO NSMP - ORANGE: Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) TransPORTEC platform trials. RAINBO - Non Specific molecular profile (NSMP) - ORANGE trial
NSMP-ORANGE is a phase III, randomised controlled trial of chemoradiation against radiotherapy with hormone therapy in patients with endometrial cancer.
Area: Gynaecological cancer
Phase: Phase III
Status: In set-up (funded)
PEACOCC
A phase II study of pembrolizumab in patients with advanced gynaecological clear cell cancer
PEACOCC is a phase II, single Arm, UK multi-centre study. All patients will receive the same dose of Pembrolizumab. All eligible patients will have advanced gynecological clear cell cancer. PEACOCC is [...]
Area: Gynaecological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
PETROC
A Phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy (PETROC/OV21)
This is an international randomised, non-blinded multicentre phase II Gynecologic Cancer Intergroup trial coordinated by the NCIC Clinical Trials Group in conjunction with SWOG (US), the Cancer Resear [...]
Area: Gynaecological cancer
Phase: Phase II
Status: Closed
PORTEC-3
Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma
PORTEC-3 is a prospective, multicentre, randomised Phase III intergroup trial led by the Dutch Cooperative Gynaecologic Oncology Group, in collaboration with the UK National Cancer Research Institute, [...]
Area: Gynaecological cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
PROMPT
A phase II study of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer
PROMPT is a phase II single-arm, UK multi-centre study. All patients will receive the same dose of Pembrolizumab. All eligible patients will have recurrent ovarian, fallopian tube or peritoneal cancer [...]
Area: Gynaecological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
SHAPE
A randomised phase III trial comparing radical hysterectomy and pelvic node dissection vs simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer
SHAPE is a multi-centre, international, prospective, randomised phase III trial of radical hysterectomy and pelvic node dissection versus simple hysterectomy and pelvic node dissection in patients wit [...]
Area: Gynaecological cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
STATEC
A randomised trial of non-Selective versus selective adjuvant Therapy in high risk Apparent sTage 1 Endometrial Cancer
STATEC is a randomised (1:1) multicentre international phase III trial of hysterectomy with lymphadenectomy vs hysterectomy alone in women with high risk apparent stage I endometrial cancer.
Area: Gynaecological cancer
Phase: Phase III
Status: Recruitment suspended
TRIOC
A phase II study to assess the activity of TroVax (MVA-5T4) versus placebo in patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer
TRIOC is a prospective multicentre phase II trial in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who develop asymptomatic relapse as confirmed by either elevated CA-1 [...]
Area: Gynaecological cancer
Phase: Phase II
Status: Closed
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2024 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us